Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Update

Vincerx Pharma, Inc. (NASDAQ:VINC) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 4,710,000 shares, a growth of 1,022.5% from the December 31st total of 419,600 shares. Based on an average daily volume of 6,840,000 shares, the days-to-cover ratio is currently 0.7 days.

Analyst Ratings Changes

Separately, Leerink Partners lowered their price target on shares of Vincerx Pharma from $80.00 to $40.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th.

Hedge Funds Weigh In On Vincerx Pharma

A hedge fund recently raised its stake in Vincerx Pharma stock. Marshall Wace LLP raised its position in Vincerx Pharma, Inc. (NASDAQ:VINC) by 359.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 328,533 shares of the company’s stock after acquiring an additional 256,967 shares during the quarter. Marshall Wace LLP owned approximately 1.11% of Vincerx Pharma worth $266,000 at the end of the most recent reporting period. Institutional investors own 44.02% of the company’s stock.

Vincerx Pharma Price Performance

VINC stock traded down $0.33 during mid-day trading on Tuesday, reaching $1.66. The company had a trading volume of 220,048 shares, compared to its average volume of 231,418. The company has a market capitalization of $55.86 million, a price-to-earnings ratio of -1.63 and a beta of 1.48. Vincerx Pharma has a 52 week low of $1.63 and a 52 week high of $187.44. The stock has a 50 day simple moving average of $0.21 and a two-hundred day simple moving average of $0.45.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.